SEC Form 4Coverage since Jun 15, 2026
$NKTR insider trading
Over the last 12 months, Nektar Therapeutics insiders reported no purchases and 3 sales totaling $1.9M across SEC Form 4 filings. 100% of the activity was filed under pre-arranged 10b5-1 trading plans.
- Bought · 12m
- — 0 events
- Sold · 12m
- $1.9M 3 events
- Events · 12m
- 3 Form 4 filings, grouped
- Insiders · 12m
- 2 distinct reporters
- 10b5-1 share
- 100% pre-arranged plans
Side
Price · $NKTR · 12Mvia TradingView
Top insiders · 12m
Zalevsky JonathanChief R&D Officer2× · $734K
ROBIN HOWARD WPresident & CEO1× · $1.2M
All insider trades
3 events
| Date | Insider | Type | Shares | Avg price | Value | Δ stake | Marks |
|---|---|---|---|---|---|---|---|
| Jun 30, 2026 | Zalevsky JonathanChief R&D Officer · O | ▼ Sale | 5,681 | $70 | $398K | -36.8% | plan |
| Jun 17, 2026 | ROBIN HOWARD WPresident & CEO · O·D | ▼ Sale | 20,000 | $60.75 | $1.2M | -26.7% | plan · 4 tranches |
| Jun 15, 2026 | Zalevsky JonathanChief R&D Officer · O | ▼ Sale | 5,538 | $60.71 | $336K | -26.4% | plan |
About Form 4
Corporate insiders — officers, directors and 10%+ owners — must report their trades to the SEC on Form 4 within two business days. We group each filing's transactions into one economic event (a laddered 10b5-1 sale is one event, not 25 rows), flag pre-arranged plans and late filings, and link every event to its AI-scored article in the $NKTR feed.